Physiogenex will be presenting a new DIO-NASH mouse study at the 82nd Scientific Sessions of the American Diabetes Association in New Orleans, LA, USA, June 3-7, 2022.

The oral presentation (#272-OR), entitled “Weight Loss with Time-Restricted Feeding or Treatment with Obeticholic Acid/Semaglutide Combination Have a Different Impact on Nonalcoholic Steatohepatitis in Diet-Induced Obese Mice” will be delivered by Dr. François Briand, our Director of Research and Development, during the Liver Pathology Session (room 220, level 2), on Monday June the 6th, 8:30-8:45am.

 Feel free to contact us if you wish to set-up an appointment with Dr. Briand during the 82nd ADA and/or discuss your drug development projects with us.

About us

 Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.